Neurocrine Biosciences (NBIX) Intangibles (2022 - 2026)

Neurocrine Biosciences (NBIX) has reported Intangibles for 5 consecutive years, with $2.2 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Intangibles rose 5883.87% year-over-year to $2.2 billion; the trailing twelve-month figure through Jun 2026 stood at $2.2 billion (up 5883.87% YoY), and the FY2025 full-year result was $4.7 million, down 87.12% from the prior year.
• Intangibles grew to $2.2 billion in Q2 2026 per NBIX's latest filing, from $4.7 million in the prior quarter.
• Across five years, Intangibles topped out at $2.2 billion in Q2 2026 and bottomed at $4.7 million in Q4 2025.
• Historically, Intangibles has averaged $190.0 million across 5 years, with a median of $36.0 million in 2025.
• The sharpest annual moves came in 2025 and 2026: Intangibles slumped 87.12% in 2025, then soared 5883.87% in 2026.
• Over 5 years, Intangibles stood at $37.2 million in 2022, then slipped by 4.57% to $35.5 million in 2023, then climbed by 2.82% to $36.5 million in 2024, then plunged by 87.12% to $4.7 million in 2025, then soared by 47261.7% to $2.2 billion in 2026.
• According to Business Quant data, Intangibles over the past three periods registered $2.2 billion, $4.7 million, and $35.7 million for Q2 2026, Q4 2025, and Q3 2025 respectively.